EA
LGND icon

Emerald Acquisition’s Ligand Pharmaceuticals LGND Stock Holding History

Emerald Acquisition’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$40.6M Buy
638,425
+46,990
+8% +$3.45M 0.08% 304
2016
Q2 		$44M Buy
+591,435
New +$43.9M 0.08% 304

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Emerald Acquisition's LGND Position: Q3 2016 in Review

Emerald Acquisition increased its Ligand Pharmaceuticals (LGND) stake by 7.9% in Q3 2016, buying an estimated $3.45M and bringing the position to 638,425 shares worth $40.6M. The position accounts for 0.08% of the portfolio, ranked #304.

Emerald Acquisition first reported a position in LGND in Q2 2016 and has held it in 2 quarters since. The position peaked at $44M in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Emerald Acquisition held 638,425 shares of Ligand Pharmaceuticals worth $40.6M as of Q3 2016.
  • Emerald Acquisition bought 46,990 Ligand Pharmaceuticals shares in Q3 2016, an estimated $3.45M.
  • Ligand Pharmaceuticals made up 0.08% of Emerald Acquisition's portfolio in Q3 2016, its #304 holding.
  • Emerald Acquisition first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Ligand Pharmaceuticals position peaked at $44M in Q2 2016.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.